

# Afschin Gandjour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4436799/publications.pdf>

Version: 2024-02-01

113  
papers

1,400  
citations

361413

20  
h-index

434195

31  
g-index

121  
all docs

121  
docs citations

121  
times ranked

1604  
citing authors

#	ARTICLE	IF	CITATIONS
1	Threshold Volumes Associated With Higher Survival in Health Care. <i>Medical Care</i> , 2003, 41, 1129-1141.	2.4	103
2	Costs of dialysis—a regional population-based analysis. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1647-1652.	0.7	66
3	Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1441-1456.	2.1	62
4	Does prevention save costs?. <i>Journal of Health Economics</i> , 2005, 24, 715-724.	2.7	48
5	Theoretical Foundation of Patient v. Population Preferences in Calculating QALYs. <i>Medical Decision Making</i> , 2010, 30, E57-E63.	2.4	41
6	Review of Quality-of-Life Evaluations in Patients with Angina Pectoris. <i>Pharmacoeconomics</i> , 1999, 16, 141-152.	3.3	37
7	An Evidence-Based Evaluation of Quality and Efficiency Indicators. <i>Quality Management in Health Care</i> , 2002, 10, 41-52.	0.8	36
8	Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases. <i>Value in Health</i> , 2018, 21, 525-531.	0.3	32
9	A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. <i>Health Policy</i> , 2007, 83, 257-267.	3.0	31
10	Consumption costs and earnings during added years of life - a reply to Nyman. <i>Health Economics (United Kingdom)</i> , 2006, 15, 315-317.	1.7	30
11	Costs of patients with chronic kidney disease in Germany. <i>PLoS ONE</i> , 2020, 15, e0231375.	2.5	30
12	How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 181-190.	2.1	29
13	When Is It Worth Introducing a Quality Improvement Program? A Mathematical Model. <i>Medical Decision Making</i> , 2003, 23, 518-525.	2.4	28
14	Cost-Effectiveness Analysis of Different Screening Procedures for Type 2 Diabetes: The KORA Survey 2000. <i>Diabetes Care</i> , 2004, 27, 2120-2128.	8.6	28
15	Nephron overload as a therapeutic target to maximize kidney lifespan. <i>Nature Reviews Nephrology</i> , 2022, 18, 171-183.	9.6	28
16	Cost-Effectiveness of Using Clinical Risk Factors with and without DXA for Osteoporosis Screening in Postmenopausal Women. <i>Value in Health</i> , 2009, 12, 1106-1117.	0.3	26
17	Mutual dependency between capabilities and functionings in Amartya Sen's capability approach. <i>Social Choice and Welfare</i> , 2008, 31, 345-350.	0.8	25
18	Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany. <i>Pharmacoeconomics</i> , 2018, 36, 1285-1296.	3.3	24

#	ARTICLE	IF	CITATIONS
19	Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG. <i>BMC Health Services Research</i> , 2020, 20, 343.	2.2	24
20	Utilitarian Theories Reconsidered: Common Misconceptions, More Recent Developments, and Health Policy Implications. <i>Health Care Analysis</i> , 2003, 11, 229-244.	2.2	23
21	European Comparison of Costs and Quality in the Treatment of Acute Back Pain. <i>Spine</i> , 2005, 30, 969-975.	2.0	23
22	Germany's Decision Rule for Setting Ceiling Prices of Drugs. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 65-71.	2.1	22
23	Cost-Effectiveness of Different Strategies for Selecting and Treating Individuals at Increased Risk of Osteoporosis or Osteopenia: A Systematic Review. <i>Value in Health</i> , 2012, 15, 284-298.	0.3	21
24	The Practice-Makes-Perfect Hypothesis in the Context of Other Production Concepts in Health Care. <i>American Journal of Medical Quality</i> , 2003, 18, 171-175.	0.5	20
25	Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model. <i>PLoS ONE</i> , 2011, 6, e26139.	2.5	20
26	Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 647-659.	2.1	19
27	Cost-Effectiveness of Preventing Hip Fractures by Hip Protectors in Elderly Institutionalized Residents in Germany. <i>Value in Health</i> , 2008, 11, 1088-1095.	0.3	18
28	Cost-Effectiveness of Implantable Defibrillators after Myocardial Infarction Based on 8-Year Follow-Up Data (MADIT II). <i>Value in Health</i> , 2011, 14, 812-817.	0.3	18
29	Direct Costs of Care in Germany for Children and Adolescents with Diabetes Mellitus in the Early Course After Onset. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2004, 17, 1551-9.	0.9	16
30	Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries. <i>Health Care Management Science</i> , 2006, 9, 359-369.	2.6	15
31	Economic evaluation of Sinfrontal® in the treatment of acute maxillary sinusitis in adults. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 181-191.	2.1	15
32	A new prize system for drug innovation. <i>Health Policy</i> , 2011, 102, 170-177.	3.0	15
33	Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 171-179.	1.4	15
34	The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. <i>Quarterly Review of Economics and Finance</i> , 2022, 84, 502-509.	2.7	15
35	Predictors of negotiated prices for new drugs in Germany. <i>European Journal of Health Economics</i> , 2020, 21, 1049-1057.	2.8	15
36	A Cost-Effectiveness Model of Screening Strategies for Amblyopia and Risk Factors and Its Application in a German Setting. <i>Optometry and Vision Science</i> , 2003, 80, 259-269.	1.2	13

#	ARTICLE	IF	CITATIONS
37	Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Applied Health Economics and Health Policy, 2008, 6, 113-135.	2.1	13
38	Ageing diseases do they prevent preventive health care from saving costs?. Health Economics (United Kingdom), 2000, 20, 13-18.	1.7	13
39	Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. International Journal of Technology Assessment in Health Care, 2010, 26, 62-70.	0.5	13
40	Empirical Validation of Patient versus Population Preferences in Calculating QALYs. Health Services Research, 2011, 46, 1562-1574.	2.0	13
41	Reference Pricing and Price Negotiations for Innovative New Drugs. Pharmacoeconomics, 2013, 31, 11-14.	3.3	13
42	How Much Does It Cost to Change the Behavior of Health Professionals? A Mathematical Model and an Application to Academic Detailing. Medical Decision Making, 2005, 25, 341-347.	2.4	12
43	A model to predict the cost-effectiveness of disease management programs. Health Economics (United Kingdom), 2001, 21, 1107-1114.	1.7	12
44	To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease - a Dutch Perspective. Kidney and Blood Pressure Research, 2013, 37, 168-180.	2.0	12
45	The German method for setting ceiling prices for drugs: in some cases less data are required. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 403-409.	1.4	11
46	Presenting Germany's drug pricing rule as a cost-per-QALY rule. Health Care Management Science, 2012, 15, 103-107.	2.6	11
47	Is subjective well-being a useful parameter for allocating resources among public interventions?. Health Care Analysis, 2001, 9, 437-447.	2.2	8
48	Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria. European Journal of Cardio-thoracic Surgery, 2003, 24, 571-577.	1.4	8
49	Convergence of decision rules for value-based pricing of new innovative drugs. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 209-213.	1.4	8
50	Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule. International Journal of Health Planning and Management, 2015, 30, 395-402.	1.7	8
51	Cost-effectiveness of future lockdown policies against the COVID-19 pandemic. Health Services Management Research, 2023, 36, 51-62.	1.7	8
52	Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany and Switzerland. International Clinical Psychopharmacology, 2004, 19, 201-208.	1.7	7
53	Incorporating feelings related to the uncertainty about future health in utility measurement. Health Economics (United Kingdom), 2008, 17, 1207-1213.	1.7	7
54	Investment in quality improvement: how to maximize the return. Health Economics (United Kingdom), 2010, 19, 31-42.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of preventing weight gain and obesity: what we know and what we need to know. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 297-305.	1.4	7
56	Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 123-129.	1.4	7
57	A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency. BMC Health Services Research, 2020, 20, 240.	2.2	7
58	Loss Aversion and Cost Effectiveness of Healthcare Programmes. Pharmacoeconomics, 2008, 26, 895-898.	3.3	6
59	Osteoporosis in German men: a cost-of-illness study. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 531-537.	1.4	6
60	Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two-step instrumental variables strategy. Health Economics (United Kingdom), 2019, 28, 101-122.	1.7	6
61	Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer's perspective. BMC Health Services Research, 2022, 22, 47.	2.2	6
62	The price of curing cancer. BMC Health Services Research, 2021, 21, 1328.	2.2	6
63	Inductive reasoning in medicine: lessons from Carl Gustav Hempel's "inductive-statistical" model. Journal of Evaluation in Clinical Practice, 2003, 9, 161-169.	1.8	5
64	The additive utility assumption of the QALY model revisited. Journal of Health Economics, 2010, 29, 325-328.	2.7	5
65	Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 215-223.	1.4	5
66	A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 341-347.	1.4	5
67	Technology assessment in dentistry: A comparison of the longevity and cost-effectiveness of inlays. International Journal of Technology Assessment in Health Care, 2005, 21, 319-325.	0.5	4
68	Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis. Applied Health Economics and Health Policy, 2011, 9, 259-273.	2.1	4
69	Comparing the validity of different measures of illness severity: a hospital-level analysis for acute myocardial infarction. Health Services Management Research, 2012, 25, 138-143.	1.7	4
70	Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach. Applied Health Economics and Health Policy, 2014, 12, 471-476.	2.1	4
71	Health care expenditures from living longer—how much do they matter. International Journal of Health Planning and Management, 2014, 29, 43-51.	1.7	4
72	Patient preferences: a Trojan horse for evidence-based medicine?. European Journal of Health Economics, 2018, 19, 167-172.	2.8	4

#	ARTICLE	IF	CITATIONS
73	Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. Applied Health Economics and Health Policy, 2020, 18, 109-125.	2.1	4
74	Impact of Demographic Changes on Healthcare Expenditures and Funding in the EU. Applied Health Economics and Health Policy, 2005, 4, 1-4.	2.1	3
75	Protocol-driven costs in trial-based pharmacoeconomic analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 673-675.	1.4	3
76	Internal validation of models with several interventions. European Journal of Health Economics, 2013, 14, 901-909.	2.8	3
77	Considering productivity loss in cost-effectiveness analysis: a new approach. European Journal of Health Economics, 2014, 15, 787-790.	2.8	3
78	Welfare gains and losses caused by clinical practice guidelines. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 27-33.	1.4	3
79	Public acceptance of different approaches to determine drug reimbursement prices and whether it is influenced by framing. International Journal of Public Sector Management, 2014, 27, 501-511.	1.8	3
80	Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results. PLoS ONE, 2020, 15, e0236543.	2.5	3
81	Value-based pricing of a COVID-19 vaccine. Quarterly Review of Economics and Finance, 2022, 84, 1-8.	2.7	3
82	Is it Rational to Pursue Utilitarianism?. Ethical Perspectives, 2007, 14, 139-158.	0.1	2
83	A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG). Health Services Management Research, 2013, 26, 103-109.	1.7	2
84	Comment on: "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines". Pharmacoeconomics, 2014, 32, 1245-1246.	3.3	2
85	Capturing Disutility from Waiting Time. Pharmacoeconomics, 2014, 32, 423-424.	3.3	2
86	A model to optimize investments in health technologies, quality of care and research. Applied Economics, 2015, 47, 2031-2039.	2.2	2
87	Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". Pharmacoeconomics, 2015, 33, 981-982.	3.3	2
88	Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation". Pharmacoeconomics, 2017, 35, 603-604.	3.3	2
89	Deterministic Sensitivity Analysis Under Ignorance. Pharmacoeconomics, 2021, 39, 1197-1198.	3.3	2
90	Financial Incentives in the Path to Recovery from the COVID-19 Pandemic. Applied Health Economics and Health Policy, 2021, 20, 5.	2.1	2

#	ARTICLE	IF	CITATIONS
91	Pharmaceutical spending and early-stage innovation in EU countries. <i>Industry and Innovation</i> , 2022, 29, 1141-1170.	3.1	2
92	An evidence-based disease-management program for patients with diabetic nephropathy. <i>Journal of Nephrology</i> , 2003, 16, 500-10.	2.0	2
93	Vaccination Mandates, Physically Forced Vaccination, and Rationing in the Intensive Care Unit: Searching for Ethical Coherence in the COVID-19 Pandemic. <i>American Journal of Bioethics</i> , 2022, 22, 11-14.	0.9	2
94	Simplifying rules for optimal allocation of preventive care resources. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 231-235.	1.4	1
95	Validation of Models That Estimate the Cost-Effectiveness of Improving Patient Adherence. <i>Value in Health</i> , 2013, 16, 1170-1171.	0.3	1
96	Commentary to: Cost of poor adherence to anti-hypertensive therapy in five European countries. <i>European Journal of Health Economics</i> , 2015, 16, 907-907.	2.8	1
97	Comment on: "The Cost Effectiveness of High-Dose Versus Conventional Haemodialysis: A Systematic Review" <i>Applied Health Economics and Health Policy</i> , 2016, 14, 729-730.	2.1	1
98	Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 507-509.	2.1	1
99	Comment on: "The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011" <i>Applied Health Economics and Health Policy</i> , 2016, 14, 241-241.	2.1	1
100	Should Cost-Effectiveness Analysis Include the Cost of Consumption Activities? AN Empirical Investigation. <i>Health Economics (United Kingdom)</i> , 2016, 25, 249-256.	1.7	1
101	Prioritizing health services research: an economic perspective. <i>European Journal of Health Economics</i> , 2016, 17, 375-377.	2.8	1
102	Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany" <i>European Journal of Health Economics</i> , 2018, 19, 471-472.	2.8	1
103	Underuse of innovative medicines in Germany: A justification for government intervention?. <i>Health Policy</i> , 2018, 122, 1283-1286.	3.0	1
104	What drives US competitiveness in mathematics and science?. <i>Educational Studies</i> , 2008, 34, 269-270.	2.4	0
105	Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 43-46.	1.4	0
106	Comment on: "Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care" <i>European Journal of Health Economics</i> , 2015, 16, 451-452.	2.8	0
107	FP396 Costs of patients with Chronic Kidney Disease in Germany. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
108	Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly. <i>European Journal of Health Economics</i> , 2020, 21, 663-664.	2.8	0

#	ARTICLE	IF	CITATIONS
109	Defining Comparators According to IQWiG's Efficiency-Frontier Method. Value in Health, 2020, 23, 674-675.	0.3	0
110	A parsimonious model to validate cost-effectiveness analyses on preventive health care. BMC Health Services Research, 2021, 21, 1213.	2.2	0
111	Optimal Sample Size Calculation for Clinical Research under a Budget Constraint. Medical Decision Making, 2022, 42, 417-418.	2.4	0
112	Demonstrating the value of cancer biomarkers at the population level. European Journal of Health Economics, 2022, , .	2.8	0
113	Comment on "Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective". Pharmacoeconomics, 0, , .	3.3	0